Department of Pharmacology Archives
Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.
Aug. 13, 2015—New findings show that fibrin, a protein that was thought to play a key role in fracture healing, is not required, shifting understanding of how fractures heal.
May. 7, 2015—Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.
Apr. 23, 2015—Preemptive genotyping: It sounds like a surprise attack, and it is.